Search results for "Vasodilator Agents"

showing 10 items of 116 documents

Degradation of phosphatidylethanol counteracts the apparent phospholipase D-mediated formation in heart and other organs.

2003

Phosphatidylalcohols, such as phosphatidylethanol (PEth), are formed from phosphatidylcholine in the presence of a primary alcohol (e.g., ethanol). This 'transphosphatidylation' reaction is used as specific phospholipase D (PLD) assay. Accumulation of PEth in tissues is recognized as a reliable measure of PLD activity, as PEth is allegedly metabolically stable. The general validity of this assumption was reinvestigated in isolated rat heart, small intestine and brain slices. The half-times of 3H-PEth degradation (labelled with 3H-myristic acid and preformed by ethanol exposure for 30 min) were about 1 h in heart and small intestine, but 17 h in brain. As the formation of PEth is superimpose…

Vasodilator AgentsIschemia610 Medicine & healthGlycerophospholipidsTritium1307 Cell BiologyRats Sprague-Dawleychemistry.chemical_compoundIschemiaPhosphatidylcholineIntestine Small1312 Molecular BiologyDiazoxidemedicinePhospholipase DAnimalsMolecular BiologyEthanolPhospholipase DMyocardiumDiazoxideBrainCell Biologymedicine.diseaseSmall intestineRatsPerfusionmedicine.anatomical_structurechemistryBiochemistry10054 Clinic for Psychiatry Psychotherapy and PsychosomaticsIschemic preconditioningPhosphatidylethanolmedicine.drugHalf-LifeBiochimica et biophysica acta
researchProduct

2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism

2014

ACS : acute coronary syndrome AMPLIFY : Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-line Therapy aPTT : activated partial thromboplastin time b.i.d. : bis in diem (twice daily) b.p.m. : beats per minute BNP : brain natriuretic peptide BP : blood pressure CI : confidence interval CO : cardiac output COPD : chronic obstructive pulmonary disease CPG : Committee for Practice Guidelines CRNM : clinically relevant non-major CT : computed tomographic/tomogram CTEPH : chronic thromboembolic pulmonary hypertension CUS : compression venous ultrasonography DSA : digital subtraction angiography DVT : deep vein thrombosis ELISA : enzyme-linked immunosorben…

Vitamin KVasodilator AgentsAdministration OralChest pain; Diagnosis; Dyspnoea; Guidelines; Heart failure; Hypotension; Pulmonary embolism; Shock; Thrombolysis; Treatment-Anticoagulation; Venousthrombosis; Administration Oral; Algorithms; Anticoagulants; Biomarkers; Chronic Disease; Clinical Laboratory Techniques; Diagnostic Imaging; Embolectomy; Endovascular Procedures; Female; Fibrin Fibrinogen Degradation Products; Fibrinolytic Agents; Heart Failure; Home Care Services; Humans; Hypertension Pulmonary; Long-Term Care; Neoplasms; Pregnancy; Pregnancy Complications Cardiovascular; Prognosis; Pulmonary Embolism; Risk Factors; Vasoconstrictor Agents; Vasodilator Agents; Vitamin K; Cardiology and Cardiovascular MedicineEmbolectomyCardiovascularChest painPregnancyRisk FactorsNeoplasmsDiagnosisVasoconstrictor AgentsSocieties MedicalEndovascular ProceduresShockGeneral MedicinePulmonaryPrognosisThrombosisThrombolysisHome Care ServicesPulmonary embolismEuropeVenous thrombosismedicine.veinPractice Guidelines as TopicAdministrationHypertensionCardiologyApixabanFemaleRadiologyHypotensionCardiology and Cardiovascular MedicineAlgorithmsmedicine.drugOralDiagnostic Imagingmedicine.medical_specialtypumonary hypertensionmedicine.drug_classHypertension PulmonaryPregnancy Complications CardiovascularCardiologyMEDLINELow molecular weight heparin610 Medicine & healthHeart failureGuidelinesInferior vena cavaFibrin Fibrinogen Degradation ProductsText miningFibrinolytic AgentsInternal medicineDyspnoeamedicineHumansIntensive care medicinebusiness.industryClinical Laboratory TechniquesPulmonary embolismAnticoagulantsTreatment-Anticoagulationmedicine.diseasePulmonary hypertensionLong-Term CarePregnancy ComplicationsVenousthrombosisHeart failureChronic DiseasebusinessBiomarkers
researchProduct

Pentaerithrityl tetranitrate improves angiotensin II induced vascular dysfunction via induction of heme oxygenase-1

2010

The organic nitrate pentaerythritol tetranitrate is devoid of nitrate tolerance, which has been attributed to the induction of the antioxidant enzyme heme oxygenase (HO)-1. With the present study, we tested whether chronic treatment with pentaerythritol tetranitrate can improve angiotensin II–induced vascular oxidative stress and dysfunction. In contrast to isosorbide-5 mononitrate (75 mg/kg per day for 7 days), treatment with pentaerythritol tetranitrate (15 mg/kg per day for 7 days) improved the impaired endothelial and smooth muscle function and normalized vascular and cardiac reactive oxygen species production (mitochondria, NADPH oxidase activity, and uncoupled endothelial NO synthase)…

medicine.medical_specialtyAntioxidantNitric Oxide Synthase Type IIImedicine.medical_treatmentVasodilator AgentsBlotting WesternFluorescent Antibody TechniquePentaerythritol tetranitratemedicine.disease_causePentaerythritolArticlechemistry.chemical_compoundInternal medicineRats Inbred SHRInternal MedicinemedicineAnimalsPentaerythritol TetranitrateEndothelial dysfunctionchemistry.chemical_classificationReactive oxygen speciesAnalysis of VarianceAngiotensin IImedicine.diseaseAngiotensin IIMitochondriaRatsHeme oxygenaseOxidative StressEndocrinologychemistryHeminEndothelium VascularReactive Oxygen SpeciesOxidative stressHeme Oxygenase-1
researchProduct

Special Considerations for Antihypertensive Agents in Dialysis Patients

2010

Hypertension is present in most patients with end-stage renal disease and likely contributes to the premature cardiovascular disease in dialysis patients. Previous practice guidelines have recommended that, in patients on chronic dialysis, blood pressure (BP) should be reduced below 130/80 mm Hg. This is based on opinions but not strong evidence, since no concrete information exists about which BP values should be the parameter to follow and which should be the target BP values. The majority of the antihypertensive agents can be used in this population, but the pharmacokinetics altered by the impaired kidney function and dialyzability influence the appropriate dosage as well as the time and…

medicine.medical_specialtyCardiotonic AgentsHypertension RenalCombination therapyMetabolic Clearance Ratemedicine.drug_classVasodilator Agentsmedicine.medical_treatmentAdrenergic beta-AntagonistsPopulationAngiotensin-Converting Enzyme InhibitorsCardiotonic AgentsRenal DialysisInternal medicinemedicineHumansDrug InteractionsDiureticseducationAntihypertensive drugAntihypertensive AgentsDialysisRandomized Controlled Trials as Topiceducation.field_of_studybusiness.industryHematologyGeneral MedicineCalcium Channel Blockersmedicine.diseaseEndocrinologyBlood pressureCardiovascular DiseasesNephrologyPractice Guidelines as TopicPolypharmacyKidney Failure ChronicDrug Therapy CombinationHemodialysisbusinessAngiotensin II Type 1 Receptor BlockersKidney diseaseBlood Purification
researchProduct

Role of Nitrates for the Therapy of Coronary Artery Disease Patients in the Years beyond 2000

1999

Vasodilator therapy with nitrates has been used for almost a century to bring relief to patients suffering from angina. The acute anti-ischemic effects of nitro-vasodilators for the treatment and prevention of anginal attacks is unquestioned. In addition, nitrates are administered in order to reduce symptomatic and silent ischemic episodes, in patients with proven coronary heart disease who exert ST segment alterations on Holter monitoring. The reduction in total ischemic burden may result in an improved prognosis with regard to infarct prevention and possible prevention of deterioration of left ventricular function due to repetitive episodes of myocardial ischemia. In patients with unstabl…

medicine.medical_specialtyCombination therapyVasodilator AgentsMyocardial InfarctionCoronary DiseaseAngina PectorisAnginaCoronary artery diseaseInternal medicinemedicineHumansMyocardial infarctionPharmacologyClinical Trials as TopicNitratesbusiness.industryUnstable anginaDrug Tolerancemedicine.diseasePreloadHeart failureACE inhibitorCardiologybusinessCardiology and Cardiovascular MedicineForecastingmedicine.drugJournal of Cardiovascular Pharmacology
researchProduct

Non-Hemodynamic Effects of Organic Nitrates and the Distinctive Characteristics of Pentaerithrityl Tetranitrate

2009

Organic nitrates are among the oldest and yet most commonly employed drugs in the long-term therapy of coronary artery disease and congestive heart failure. While they have long been used in clinical practice, our understanding of their mechanism of action and side effects remains incomplete. For instance, recent findings provide evidence of previously unanticipated, non-hemodynamic properties that include potentially beneficial mechanisms (such as the induction of a protective phenotype that mimics ischemic preconditioning), but also toxic effects (such as endothelial and autonomic dysfunction, rebound angina, tolerance). To date, the most commonly employed organic nitrates are isosorbide …

medicine.medical_specialtyHeart DiseasesVasodilator AgentsIsosorbide DinitratePharmacologyDrug Administration ScheduleAnginaCoronary artery diseaseNitroglycerinmedicineIsosorbide mononitrateAnimalsHumansPentaerythritol TetranitratePharmacology (medical)NitroglycerinNitratesbusiness.industryDrug ToleranceGeneral Medicinemedicine.diseaseSurgeryEastern europeanOxidative StressHeart failureIschemic preconditioningIsosorbide dinitrateReactive Oxygen SpeciesCardiology and Cardiovascular Medicinebusinessmedicine.drugAmerican Journal of Cardiovascular Drugs
researchProduct

Long-term prognostic implications of revascularization in patients with known or suspected chronic coronary syndromes without ischemia in vasodilator…

2021

In this study, we evaluated the association between symptoms-guided revascularization occurred within three months following a negative vasodilator stress cardiovascular magnetic resonance (negative stress-CMR) and long-term adverse events in patients with known or suspected chronic coronary syndrome (CCS).We retrospectively evaluated 3517 patients in which the stress first-pass perfusion imaging revealed no ischemia. The primary endpoint was the composite of death, spontaneous myocardial infarction, heart failure (HF), or stroke. The association between symptoms-guided revascularization after a negative stress-CMR and the endpoint was assessed using the multivariable Cox proportional hazar…

medicine.medical_specialtyMagnetic Resonance SpectroscopyVasodilator Agentsmedicine.medical_treatmentMyocardial InfarctionIschemiaPerfusion scanningCoronary Artery Disease030204 cardiovascular system & hematologyRevascularization03 medical and health sciences0302 clinical medicinePredictive Value of TestsInternal medicinemedicineClinical endpointHumans030212 general & internal medicineMyocardial infarctionStrokeAgedRetrospective Studiesmedicine.diagnostic_testbusiness.industryMagnetic resonance imagingSyndromeMiddle AgedPrognosismedicine.diseaseMagnetic Resonance ImagingHeart failureCardiologyFemaleCardiology and Cardiovascular MedicinebusinessInternational Journal of Cardiology
researchProduct

Stress cardiac magnetic resonance for mortality prediction and decision-making: registry of 2496 elderly patients with chronic coronary syndrome

2022

Abstract Introduction and objectives The management of elderly patients with chronic coronary syndrome (CCS) is challenging. We explored the prognostic value and usefulness for decision-making of ischemic burden determined by vasodilator stress cardiac magnetic resonance (CMR) imaging in elderly patients with known or suspected CCS. Methods The study group comprised 2496 patients older than 70 years who underwent vasodilator stress CMR for known or suspected CCS. The ischemic burden (number of segments with stress-induced perfusion deficit) was calculated following the 17-segment model. Subsequently, we retrospectively analyzed its association with all-cause mortality and the effect of CMR-…

medicine.medical_specialtyMagnetic Resonance SpectroscopyVasodilator stressVasodilator Agentsmedicine.medical_treatmentIschemiaMagnetic Resonance Imaging CineCoronary Artery DiseaseIndependent predictorRevascularizationPredictive Value of TestsRisk FactorsInternal medicinemedicineHumansIn patientRegistriesMortality predictionAgedRetrospective Studiesbusiness.industryGeneral MedicinePrognosismedicine.diseaseMagnetic Resonance ImagingCardiologyFemalebusinessCardiac magnetic resonancePerfusionRevista Española de Cardiología (English Edition)
researchProduct

Comparing the Outcomes of Different Agents to Treat Vasospasm at Microsurgical Anastomosis during the Papaverine Shortage.

2017

Letter to Editor

medicine.medical_specialtyPapaverinemicrosurgery anastomosisbusiness.industryVasodilator AgentsSettore MED/19 - Chirurgia PlasticaMEDLINEEconomic shortageVasospasmmedicine.diseaseMicrosurgical anastomosisSurgery030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineVasodilator agentsVasoconstriction030220 oncology & carcinogenesisPapaverinemedicineHumansSurgeryVascular Diseasesbusinessmedicine.drugPlastic and reconstructive surgery
researchProduct

Pentobarbital-sensitive EDHF comediates ACh-induced arteriolar dilation in the hamster microcirculation

1999

It is unclear to what extent the endothelium-derived hyperpolarizing factor (EDHF) contributes to the control of microcirculatory blood flow in vivo. We analyzed, by intravital microscopy in hamster muscles, the potential role of EDHF along the vascular tree under stimulated (ACh) or basal conditions. Experiments were performed in conscious as well as anesthetized (pentobarbital, urethan) animals. Additionally, cellular effects of the potential EDHF were studied in isolated small arteries. In pentobarbital-anesthetized animals, treatment with N ω-nitro-l-arginine (l-NNA; 30 μmol/l) and indomethacin (3 μmol/l) reduced the dilation in response to 10 μmol/l ACh from 60 ± 6 to 20 ± 4%. This ni…

medicine.medical_specialtyPentobarbitalEndothelium-derived hyperpolarizing factorPotassium ChannelsCharybdotoxinPhysiologyVasodilator AgentsIndomethacinHamsterVasodilationNitroarginineMuscle Smooth VascularMicrocirculationGlibenclamideBiological FactorsCytochrome P-450 Enzyme SystemArterioleCricetinaePhysiology (medical)Internal medicinemedicine.arterymedicineAnimalsCyclooxygenase InhibitorsMuscle SkeletalPentobarbitalSkinMesocricetusChemistryMicrocirculationPenicillamineAcetylcholineArteriolesEndocrinologyAnesthesiaFatty Acids UnsaturatedPotassiumEndothelium VascularCardiology and Cardiovascular MedicineIntravital microscopyAdjuvants Anesthesiamedicine.drugAmerican Journal of Physiology-Heart and Circulatory Physiology
researchProduct